Longeveron Co-Chairs, Hosts Symposium At The 2019 World Stem Cell Summit And Phacilitate Leaders World Conferences In Miami
NEWS PROVIDED BY
Jan 18, 2019, 09:35 ET
MIAMI, Jan. 18, 2019 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops cellular therapies for aging-related diseases, will play a prominent role when leading experts gather in Miami for the 2019 World Stem Cell Summit, Jan. 22-25 at the Hyatt Regency Hotel.
One of the largest conferences dedicated to regenerative medicine, the World Stem Cell Summit brings together leading scientists and clinicians, investors, legal experts, funders and regulators. WSCS is held in conjunction with partner events, Phacilitate Leaders World, Cell & Gene Therapy World and Immuno-Oncology Frontiers World. The combined conferences attract more than 1,500 attendees from around the world, feature more than 300 global speakers, and have more than 90 hours of programming on the latest advances in regenerative medicine.
“We are very pleased to be a host in our hometown of Miami as the world’s most prominent researchers and experts come together to discuss new developments and share the latest innovations in this rapidly-growing field, which we believe holds great promise for the future of healthcare,” said Suzanne Page, Chief Operating Officer of Longeveron, which is serving as a co-chair of the event.
On Wednesday, Jan. 23, from 12:30 to 1:30 pm, Longeveron will host a briefing on “Trends in Biotechnology Research Aimed at Extending Health Lifespan.” On Thursday, Jan. 24, at 2:35 pm, Longeveron will discuss the company’s progress with its clinical research studying the safety and efficacy of stem cell treatments for aging-related diseases as part of a session on “Neurology and aging diseases: Giving neurology patients new hope through stem cell research.” Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases, including Aging Frailty and Alzheimer’s Disease.
In 2017, the company published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its stem cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2bAging Frailty study.
The company is also recruiting for a Phase 1 Alzheimer’s trial, as well as Phase 1 and Phase 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. The company’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
SOURCE Longeveron LLC